Evidence map›Paper›PMID 31659386›Full record

ArticleIntensive care medicine2020

Should we consider blocking the inhibitory immune checkpoint molecules for treating T cell exhaustion in sepsis?

Manu Shankar-Hari, Matthew Fish, Elie Azoulay

Open access · bronzeAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Extracellular vesicle-associated PD-L1 induces CD4Cell communication and signaling : CCS · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Focus on sepsis.Intensive care medicine · 2020
    Article
  9. Article
  10. COVID-19: room for treating T cell exhaustion?Critical care (London, England) · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Manu Shankar-HariSchool of Immunology and Microbial Sciences, King's College London, 5th Floor, Southwark Wing, London, SE1 9RT, UK. manu.shankar-hari@kcl.ac.uk.ORCID http://orcid.org/0000-0002-5338-2538
Matthew FishSchool of Immunology and Microbial Sciences, King's College London, 5th Floor, Southwark Wing, London, SE1 9RT, UK.
Elie AzoulayUniversity of Paris-Diderot, Sorbonne Paris-Cité, Paris, France.
Délégation Paris 7 · FRKing's College London · GBSt Thomas' Hospital · GB

Funding

Department of Health CS-2016-16-011Research Trainees Coordinating Centre CS-2016-16-011
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

SepsisT-LymphocytesHumansImmunotherapyNivolumabNivolumab

Identifiers

PMID31659386
OpenAlexW2982563600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.